What is the current valuation of the Vaccine Research Market as of 2024?

The Vaccine Research Market was valued at 58.71 USD Billion in 2024. Read More

What is the projected market valuation for the Vaccine Research Market in 2035?

The projected valuation for the Vaccine Research Market in 2035 is 270.84 USD Billion. Read More

What is the expected CAGR for the Vaccine Research Market during the forecast period 2025 - 2035?

The expected CAGR for the Vaccine Research Market during the forecast period 2025 - 2035 is 14.91%. Read More

Which companies are considered key players in the Vaccine Research Market?

Key players in the Vaccine Research Market include Pfizer, Moderna, Johnson & Johnson, AstraZeneca, Sanofi, GSK, Novavax, Merck, and Bharat Biotech. Read More

What are the market segments for Vaccine Research based on vaccine type?

Market segments for Vaccine Research based on vaccine type include Live Attenuated, Inactivated, Recombinant, Conjugate, Subunit, Viral Vector, DNA, and mRNA Vaccines. Read More

What was the market size for Live Attenuated Vaccines in 2024?

The market size for Live Attenuated Vaccines was 8.0 USD Billion in 2024. Read More

How much is the market for Inactivated Vaccines projected to grow by 2035?

The market for Inactivated Vaccines is projected to grow to 45.0 USD Billion by 2035. Read More

What is the expected market size for Chronic Diseases vaccine segment by 2035?

The expected market size for the Chronic Diseases vaccine segment is projected to reach 80.0 USD Billion by 2035. Read More

Which target population segment has the highest market size in 2024?

In 2024, the Adults target population segment had the highest market size at 20.0 USD Billion. Read More

What delivery method segment is anticipated to have the largest market size by 2035?

The Intramuscular Injection delivery method segment is anticipated to have the largest market size, projected at 90.0 USD Billion by 2035. Read More

Vaccine Research Market

ID: MRFR/HC/26248-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Vaccine Research Market Research Report By Vaccine Type (Live Attenuated Vaccines, Inactivated Vaccines, Recombinant Vaccines, Conjugate Vaccines, Subunit Vaccines, Viral Vector Vaccines, DNA Vaccines, mRNA Vaccines), By Disease Prevention (Infectious Diseases (e.g., Measles, Polio, Influenza), Chronic Diseases (e.g., Cancer, HIV/AIDS), Rare Diseases (e.g., Cystic Fibrosis, Hemophilia)), By Target Population (Pediatrics, Adults, Elderly, Pregnant Women), By Delivery Method (Intramuscular Injection, Subcutaneous Injection, Intranasal Delivery, Oral Administration) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Healthcare, BY Type (USD Billion)
4.1.1 Live Attenuated Vaccines
4.1.2 Inactivated Vaccines
4.1.3 Recombinant Vaccines
4.1.4 Conjugate Vaccines
4.1.5 Subunit Vaccines
4.1.6 Viral Vector Vaccines
4.1.7 DNA Vaccines
4.1.8 mRNA Vaccines
4.2 Healthcare, BY Disease Prevention (USD Billion)
4.2.1 Infectious Diseases
4.2.2 Chronic Diseases
4.2.3 Rare Diseases
4.3 Healthcare, BY Target Population (USD Billion)
4.3.1 Pediatrics
4.3.2 Adults
4.3.3 Elderly
4.3.4 Pregnant Women
4.4 Healthcare, BY Delivery Method (USD Billion)
4.4.1 Intramuscular Injection
4.4.2 Subcutaneous Injection
4.4.3 Intranasal Delivery
4.4.4 Oral Administration
4.5 Healthcare, BY Region (USD Billion)
4.5.1 North America
4.5.1.1 US
4.5.1.2 Canada
4.5.2 Europe
4.5.2.1 Germany
4.5.2.2 UK
4.5.2.3 France
4.5.2.4 Russia
4.5.2.5 Italy
4.5.2.6 Spain
4.5.2.7 Rest of Europe
4.5.3 APAC
4.5.3.1 China
4.5.3.2 India
4.5.3.3 Japan
4.5.3.4 South Korea
4.5.3.5 Malaysia
4.5.3.6 Thailand
4.5.3.7 Indonesia
4.5.3.8 Rest of APAC
4.5.4 South America
4.5.4.1 Brazil
4.5.4.2 Mexico
4.5.4.3 Argentina
4.5.4.4 Rest of South America
4.5.5 MEA
4.5.5.1 GCC Countries
4.5.5.2 South Africa
4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Healthcare
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Pfizer (US)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 Moderna (US)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 Johnson & Johnson (US)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 AstraZeneca (GB)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Sanofi (FR)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 GSK (GB)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Novavax (US)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Merck (US)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.2.9 Bharat Biotech (IN)
5.2.9.1 Financial Overview
5.2.9.2 Products Offered
5.2.9.3 Key Developments
5.2.9.4 SWOT Analysis
5.2.9.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY TYPE
6.4 US MARKET ANALYSIS BY DISEASE PREVENTION
6.5 US MARKET ANALYSIS BY TARGET POPULATION
6.6 US MARKET ANALYSIS BY DELIVERY METHOD
6.7 CANADA MARKET ANALYSIS BY TYPE
6.8 CANADA MARKET ANALYSIS BY DISEASE PREVENTION
6.9 CANADA MARKET ANALYSIS BY TARGET POPULATION
6.10 CANADA MARKET ANALYSIS BY DELIVERY METHOD
6.11 EUROPE MARKET ANALYSIS
6.12 GERMANY MARKET ANALYSIS BY TYPE
6.13 GERMANY MARKET ANALYSIS BY DISEASE PREVENTION
6.14 GERMANY MARKET ANALYSIS BY TARGET POPULATION
6.15 GERMANY MARKET ANALYSIS BY DELIVERY METHOD
6.16 UK MARKET ANALYSIS BY TYPE
6.17 UK MARKET ANALYSIS BY DISEASE PREVENTION
6.18 UK MARKET ANALYSIS BY TARGET POPULATION
6.19 UK MARKET ANALYSIS BY DELIVERY METHOD
6.20 FRANCE MARKET ANALYSIS BY TYPE
6.21 FRANCE MARKET ANALYSIS BY DISEASE PREVENTION
6.22 FRANCE MARKET ANALYSIS BY TARGET POPULATION
6.23 FRANCE MARKET ANALYSIS BY DELIVERY METHOD
6.24 RUSSIA MARKET ANALYSIS BY TYPE
6.25 RUSSIA MARKET ANALYSIS BY DISEASE PREVENTION
6.26 RUSSIA MARKET ANALYSIS BY TARGET POPULATION
6.27 RUSSIA MARKET ANALYSIS BY DELIVERY METHOD
6.28 ITALY MARKET ANALYSIS BY TYPE
6.29 ITALY MARKET ANALYSIS BY DISEASE PREVENTION
6.30 ITALY MARKET ANALYSIS BY TARGET POPULATION
6.31 ITALY MARKET ANALYSIS BY DELIVERY METHOD
6.32 SPAIN MARKET ANALYSIS BY TYPE
6.33 SPAIN MARKET ANALYSIS BY DISEASE PREVENTION
6.34 SPAIN MARKET ANALYSIS BY TARGET POPULATION
6.35 SPAIN MARKET ANALYSIS BY DELIVERY METHOD
6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
6.37 REST OF EUROPE MARKET ANALYSIS BY DISEASE PREVENTION
6.38 REST OF EUROPE MARKET ANALYSIS BY TARGET POPULATION
6.39 REST OF EUROPE MARKET ANALYSIS BY DELIVERY METHOD
6.40 APAC MARKET ANALYSIS
6.41 CHINA MARKET ANALYSIS BY TYPE
6.42 CHINA MARKET ANALYSIS BY DISEASE PREVENTION
6.43 CHINA MARKET ANALYSIS BY TARGET POPULATION
6.44 CHINA MARKET ANALYSIS BY DELIVERY METHOD
6.45 INDIA MARKET ANALYSIS BY TYPE
6.46 INDIA MARKET ANALYSIS BY DISEASE PREVENTION
6.47 INDIA MARKET ANALYSIS BY TARGET POPULATION
6.48 INDIA MARKET ANALYSIS BY DELIVERY METHOD
6.49 JAPAN MARKET ANALYSIS BY TYPE
6.50 JAPAN MARKET ANALYSIS BY DISEASE PREVENTION
6.51 JAPAN MARKET ANALYSIS BY TARGET POPULATION
6.52 JAPAN MARKET ANALYSIS BY DELIVERY METHOD
6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
6.54 SOUTH KOREA MARKET ANALYSIS BY DISEASE PREVENTION
6.55 SOUTH KOREA MARKET ANALYSIS BY TARGET POPULATION
6.56 SOUTH KOREA MARKET ANALYSIS BY DELIVERY METHOD
6.57 MALAYSIA MARKET ANALYSIS BY TYPE
6.58 MALAYSIA MARKET ANALYSIS BY DISEASE PREVENTION
6.59 MALAYSIA MARKET ANALYSIS BY TARGET POPULATION
6.60 MALAYSIA MARKET ANALYSIS BY DELIVERY METHOD
6.61 THAILAND MARKET ANALYSIS BY TYPE
6.62 THAILAND MARKET ANALYSIS BY DISEASE PREVENTION
6.63 THAILAND MARKET ANALYSIS BY TARGET POPULATION
6.64 THAILAND MARKET ANALYSIS BY DELIVERY METHOD
6.65 INDONESIA MARKET ANALYSIS BY TYPE
6.66 INDONESIA MARKET ANALYSIS BY DISEASE PREVENTION
6.67 INDONESIA MARKET ANALYSIS BY TARGET POPULATION
6.68 INDONESIA MARKET ANALYSIS BY DELIVERY METHOD
6.69 REST OF APAC MARKET ANALYSIS BY TYPE
6.70 REST OF APAC MARKET ANALYSIS BY DISEASE PREVENTION
6.71 REST OF APAC MARKET ANALYSIS BY TARGET POPULATION
6.72 REST OF APAC MARKET ANALYSIS BY DELIVERY METHOD
6.73 SOUTH AMERICA MARKET ANALYSIS
6.74 BRAZIL MARKET ANALYSIS BY TYPE
6.75 BRAZIL MARKET ANALYSIS BY DISEASE PREVENTION
6.76 BRAZIL MARKET ANALYSIS BY TARGET POPULATION
6.77 BRAZIL MARKET ANALYSIS BY DELIVERY METHOD
6.78 MEXICO MARKET ANALYSIS BY TYPE
6.79 MEXICO MARKET ANALYSIS BY DISEASE PREVENTION
6.80 MEXICO MARKET ANALYSIS BY TARGET POPULATION
6.81 MEXICO MARKET ANALYSIS BY DELIVERY METHOD
6.82 ARGENTINA MARKET ANALYSIS BY TYPE
6.83 ARGENTINA MARKET ANALYSIS BY DISEASE PREVENTION
6.84 ARGENTINA MARKET ANALYSIS BY TARGET POPULATION
6.85 ARGENTINA MARKET ANALYSIS BY DELIVERY METHOD
6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE PREVENTION
6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET POPULATION
6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DELIVERY METHOD
6.90 MEA MARKET ANALYSIS
6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
6.92 GCC COUNTRIES MARKET ANALYSIS BY DISEASE PREVENTION
6.93 GCC COUNTRIES MARKET ANALYSIS BY TARGET POPULATION
6.94 GCC COUNTRIES MARKET ANALYSIS BY DELIVERY METHOD
6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
6.96 SOUTH AFRICA MARKET ANALYSIS BY DISEASE PREVENTION
6.97 SOUTH AFRICA MARKET ANALYSIS BY TARGET POPULATION
6.98 SOUTH AFRICA MARKET ANALYSIS BY DELIVERY METHOD
6.99 REST OF MEA MARKET ANALYSIS BY TYPE
6.100 REST OF MEA MARKET ANALYSIS BY DISEASE PREVENTION
6.101 REST OF MEA MARKET ANALYSIS BY TARGET POPULATION
6.102 REST OF MEA MARKET ANALYSIS BY DELIVERY METHOD
6.103 KEY BUYING CRITERIA OF HEALTHCARE
6.104 RESEARCH PROCESS OF MRFR
6.105 DRO ANALYSIS OF HEALTHCARE
6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
6.111 HEALTHCARE, BY DISEASE PREVENTION, 2024 (% SHARE)
6.112 HEALTHCARE, BY DISEASE PREVENTION, 2024 TO 2035 (USD Billion)
6.113 HEALTHCARE, BY TARGET POPULATION, 2024 (% SHARE)
6.114 HEALTHCARE, BY TARGET POPULATION, 2024 TO 2035 (USD Billion)
6.115 HEALTHCARE, BY DELIVERY METHOD, 2024 (% SHARE)
6.116 HEALTHCARE, BY DELIVERY METHOD, 2024 TO 2035 (USD Billion)
6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY TYPE, 2025-2035 (USD Billion)
7.2.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.2.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.2.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY TYPE, 2025-2035 (USD Billion)
7.3.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.3.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.3.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY TYPE, 2025-2035 (USD Billion)
7.4.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.4.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.4.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY TYPE, 2025-2035 (USD Billion)
7.5.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.5.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.5.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY TYPE, 2025-2035 (USD Billion)
7.6.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.6.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.6.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY TYPE, 2025-2035 (USD Billion)
7.7.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.7.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.7.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY TYPE, 2025-2035 (USD Billion)
7.8.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.8.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.8.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY TYPE, 2025-2035 (USD Billion)
7.9.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.9.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.9.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY TYPE, 2025-2035 (USD Billion)
7.10.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.10.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.10.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY TYPE, 2025-2035 (USD Billion)
7.11.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.11.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.11.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY TYPE, 2025-2035 (USD Billion)
7.12.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.12.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.12.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY TYPE, 2025-2035 (USD Billion)
7.13.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.13.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.13.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY TYPE, 2025-2035 (USD Billion)
7.14.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.14.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.14.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY TYPE, 2025-2035 (USD Billion)
7.15.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.15.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.15.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY TYPE, 2025-2035 (USD Billion)
7.16.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.16.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.16.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY TYPE, 2025-2035 (USD Billion)
7.17.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.17.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.17.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY TYPE, 2025-2035 (USD Billion)
7.18.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.18.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.18.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY TYPE, 2025-2035 (USD Billion)
7.19.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.19.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.19.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY TYPE, 2025-2035 (USD Billion)
7.20.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.20.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.20.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY TYPE, 2025-2035 (USD Billion)
7.21.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.21.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.21.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY TYPE, 2025-2035 (USD Billion)
7.22.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.22.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.22.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY TYPE, 2025-2035 (USD Billion)
7.23.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.23.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.23.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY TYPE, 2025-2035 (USD Billion)
7.24.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.24.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.24.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY TYPE, 2025-2035 (USD Billion)
7.25.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.25.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.25.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY TYPE, 2025-2035 (USD Billion)
7.26.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.26.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.26.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY TYPE, 2025-2035 (USD Billion)
7.27.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.27.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.27.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY TYPE, 2025-2035 (USD Billion)
7.28.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.28.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.28.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY TYPE, 2025-2035 (USD Billion)
7.29.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.29.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.29.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY TYPE, 2025-2035 (USD Billion)
7.30.2 BY DISEASE PREVENTION, 2025-2035 (USD Billion)
7.30.3 BY TARGET POPULATION, 2025-2035 (USD Billion)
7.30.4 BY DELIVERY METHOD, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

Live Attenuated Vaccines
Inactivated Vaccines
Recombinant Vaccines
Conjugate Vaccines
Subunit Vaccines
Viral Vector Vaccines
DNA Vaccines
mRNA Vaccines

Healthcare By Disease Prevention (USD Billion, 2025-2035)

Infectious Diseases
Chronic Diseases
Rare Diseases

Healthcare By Target Population (USD Billion, 2025-2035)

Pediatrics
Adults
Elderly
Pregnant Women

Healthcare By Delivery Method (USD Billion, 2025-2035)

Intramuscular Injection
Subcutaneous Injection
Intranasal Delivery
Oral Administration

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓